Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer (Q34283691)

1 August 2017

title

Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer (English)

1 reference

1 August 2017

8

Toyomasa Katagiri

1 reference

1 August 2017

Wataru Obara

1

1 reference

1 August 2017

Ryuji Ohsawa

2

1 reference

1 August 2017

Mitsugu Kanehira

3

1 reference

1 August 2017

Ryo Takata

4

1 reference

1 August 2017

Takuya Tsunoda

5

1 reference

1 August 2017

Koji Yoshida

6

1 reference

1 August 2017

Kazuyoshi Takeda

7

1 reference

1 August 2017

Yusuke Nakamura

9

1 reference

1 August 2017

Tomoaki Fujioka

10

1 reference

1 August 2017

publication date

25 May 2012

1 reference

Japanese Journal of Clinical Oncology

1 August 2017

published in

1 reference

1 August 2017

volume

42

1 reference

1 August 2017

issue

7

1 reference

1 August 2017

page(s)

591-600

1 reference

1 August 2017

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS069

Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS069

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS069

Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS069

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS069

Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS069

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS069

L-BLP25: a peptide vaccine strategy in non small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS069

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS069

Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS069

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS069

Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS069

Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS069

Oncogenic role of MPHOSPH1, a cancer-testis antigen specific to human bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS069

Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS069

Ring finger protein 43 as a new target for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS069

Identification of immunoglobulin superfamily 11 (IGSF11) as a novel target for cancer immunotherapy of gastrointestinal and hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS069

Identification of secernin 1 as a novel immunotherapy target for gastric cancer using the expression profiles of cDNA microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS069

Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS069

Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS069

Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS069

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS069

Immunomonitoring Tumor-Specific T Cells in Delayed-Type Hypersensitivity Skin Biopsies After Dendritic Cell Vaccination Correlates With Clinical Outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYS069

21 January 2018

Identifiers

DOI

10.1093/JJCO/HYS069

1 reference

1 August 2017

1 reference